Evolution of the Average Target: UCB

Evolution of the Target Price: UCB

Changes in Analyst Recommendations: UCB

cbdbe040e8f70a4d1a8.0hfIxpeMsldGyDlCttEaV9xgFnmXdA0FpT7LfT2mqto.pFGdtfr8yg5wsH928qhVJO0zWCzwR3pK0U_7PGWe4Ju1VaGs7eTHOiSETg~d20f8b4e3104e03ff2dd1216972c0188
03/07 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
22/06 UBS Trims UCB's PT, Affirms Buy Rating MT
15/06 UCB Slumps Following Analyst Downgrade Zonebourse
15/06 Barclays Downgrades UCB to Equalweight, Trims PT MT
15/06 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT
09/06 UCB Favored by Oddo BHF Zonebourse
05/06 KBC Securities Maintains Buy Rating on UCB Zonebourse
21/05 UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum MT
20/05 UCB: Executing well, but valuation lacks safety net Alphavalue
27/04 AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT MT
30/03 MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says MT
16/03 Berenberg says Belgian drugmaker UCB stock is undervalued Zonebourse
16/03 Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts MT
26/02 UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot Alphavalue
24/02 Wolfe Research Kicks Off UCB Coverage at Outperform MT
02/02 UCB on Track for 'Impressive' Growth Acceleration, Says RBC MT
07/01 BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook MT
06/01 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
03/12 Berenberg Keeps UCB at Buy Amid Plan to Maximize Growth of Key Assets MT
29/25/29 UCB: UBS raises target price Zonebourse
14/25/14 Berenberg Says Higher Premium for UCB Pipeline Warranted; Price Target Raised MT
13/25/13 UCB Announces Results from Multicenter Retrospective Chart Review Study of Investigational Pyrimidine Nucleoside and/or nucleotide Therapy in Patients with Thymidine Kinase 2 Deficiency CI
07/25/07 AlphaValue/Baader Europe Lifts UCB Price Target Amid Strong Drug Demand MT
03/25/03 UCB: Untouchable UCB; despite our upgrade Alphavalue
29/25/29 MoonLake Shares Slide After Release of Skin Disorder Drug Trial Data, Multiple Downgrades MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+13.19%
+27%
+46.37%
+12.1%
-43.95%
+6.48%
-3.76%
+29.59%
+1.13%
+31.55%
Average +11.97%
Weighted average by Cap. +13.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
254.40EUR
Average target price
287.95EUR
Spread / Average Target
+13.19%
High Price Target
340.00EUR
Spread / Highest target
+33.65%
Low Price Target
195.00EUR
Spread / Lowest Target
-23.35%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Barclays
alphavalue Abhishek Raval
AlphaValue/Baader Europe
Wolfe Research
Bank Degroof Petercam
Morgan Stanley
Intron Health
Sadif Investment Analytics
Kempen
KBC Securities
ODDO BHF
Kepler Cheuvreux
Berenberg Bank
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
254.40EUR
Average target price
287.95EUR
Spread / Average Target
+13.19%

Quarterly revenue - Rate of surprise